J D Baumgartner|M P Glauser - JoVE Visualize

Showing results (201-210 of 210) with videos related to

Pageof 21

Sort By:

You have reached the last page of results.This site can display upto 210 results.

Circulation|August 18, 1999

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort StudyD Périard, A Telenti, P Sudre, et al.

Critical Care Medicine|July 9, 1999

Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patientsP Eggimann, P Francioli, J Bille, et al.

Antimicrobial Agents and Chemotherapy|June 1, 1994

Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patientsA Cometta, J D Baumgartner, D Lew, et al.

JAMA|May 21, 1997

p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study GroupE Abraham, M P Glauser, T Butler, et al.

Antimicrobial Agents and Chemotherapy|October 31, 1998

Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitisC Jaccard, N Troillet, S Harbarth, et al.

European Journal of Immunology|February 17, 1998

Genetic polymorphism of CCR5 gene and HIV disease: the heterozygous (CCR5/delta ccr5) genotype is neither essential nor sufficient for protection against disease progression. Swiss HIV CohortR A Morawetz, G P Rizzardi, D Glauser, et al.

Antimicrobial Agents and Chemotherapy|October 25, 2003

Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized studyG Zanetti, F Bally, G Greub, et al.

Antimicrobial Agents and Chemotherapy|May 1, 1996

Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection ProgramA Cometta, T Calandra, H Gaya, et al.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 29, 2003

Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapyA Cometta, W V Kern, R De Bock, et al.

Nature Medicine|July 14, 1998

Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapyS Fleury, R J de Boer, G P Rizzardi, et al.

Pageof 21

Showing results (201-210 of 210) with videos related to

Sort By:

Pageof 21

You have reached the last page of results.This site can display upto 210 results.

Circulation|August 18, 1999

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort StudyD Périard, A Telenti, P Sudre, et al.

Critical Care Medicine|July 9, 1999

Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patientsP Eggimann, P Francioli, J Bille, et al.

Antimicrobial Agents and Chemotherapy|June 1, 1994

Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patientsA Cometta, J D Baumgartner, D Lew, et al.

JAMA|May 21, 1997

p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study GroupE Abraham, M P Glauser, T Butler, et al.

Antimicrobial Agents and Chemotherapy|October 31, 1998

Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitisC Jaccard, N Troillet, S Harbarth, et al.

European Journal of Immunology|February 17, 1998

Genetic polymorphism of CCR5 gene and HIV disease: the heterozygous (CCR5/delta ccr5) genotype is neither essential nor sufficient for protection against disease progression. Swiss HIV CohortR A Morawetz, G P Rizzardi, D Glauser, et al.

Antimicrobial Agents and Chemotherapy|October 25, 2003

Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized studyG Zanetti, F Bally, G Greub, et al.

Antimicrobial Agents and Chemotherapy|May 1, 1996

Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection ProgramA Cometta, T Calandra, H Gaya, et al.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 29, 2003

Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapyA Cometta, W V Kern, R De Bock, et al.

Nature Medicine|July 14, 1998

Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapyS Fleury, R J de Boer, G P Rizzardi, et al.

Pageof 21